Beard SM, McCrink L, Le TK, Garcia-Cebrian A, Monz B, Malik RA. Cost effectiveness of duloxetine in the treatment of diabetic peripheral neuropathic pain in the UK. Curr Med Res Opin. 2008 Feb;24(2):385-99.
Earnshaw SR, Graham CN, Ettinger B, Amonkar MM, Lynch NO, Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr Med Res Opin. 2007 Oct 1;23(10):2517-29.
Yood MU, Lafata JE, Koro C, Wells KE, Pladevall-Vila M. Time to pharmacotherapy change in response to elevated HbA(1c) test results. Curr Med Res Opin. 2006 Aug;22(8):1567-74.
Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord. 2006 Feb 1;90(2-3):217-21.
Portenoy R, ID Pain Steering Committee, McLeod LD. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin. 2006;22(8):1555-65.
Mladsi DM, Grogg AL, Irish WD, Lopez RB, Degen K, Swann A, Nimsch CT. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. Curr Med Res Opin. 2004 Jan 1;20(12):1883-93. doi: 10.1185/030079904X11510.
McKenna SP, Doward LC, Kohlmann T, Mercier C, Niero M, Paes M, Patrick D, Ramirez N, Thorsen H, Whalley D. International development of the Quality of Life in Depression Scale (QLDS). J Affect Disord. 2001 Mar 1;63(1-3):189-99.
Loughlin JE, Rothman KJ, Dreyer NA. Lymphatic and haematopoietic cancer mortality in a population attending school adjacent to styrene-butadiene facilities, 1963-1993. J Epidemiol Community Health. 1999 Jan 1;53(5):283-7.
Poole C, Rothman KJ. Our conscientious objection to the epidemiology wars. J Epidemiol Community Health. 1998 Oct 1;52(10):613-4.